October 15, 2024
Sponsored by Thermo Fisher Scientific
This article discusses the increasing reliance of biopharmaceutical drug innovators on contract development and manufacturing organizations (CDMOs) as the market evolves and continues to grow. The work of CDMOs allows major pharmaceutical companies to outsource parts of their business, enabling them to scale their manufacturing and focus on drug discovery and delivery. The article emphasizes the importance of CDMOs focusing on their core mission to develop and manufacture drugs for their clients, while seeking cost-effective solutions for non-core activities leading up to the core production jobs.
The article suggests that by partnering with industry experts, CDMOs can streamline their workflows, resulting in greater efficiencies, lower operational costs, and avoidance of capital expenditures. It provides an example of such a partnership in the area of supply chain management, where a distribution partner can perform critical jobs, maintain inventory of critical materials, and provide just-in-time delivery.
The article also highlights:
The role of chemical workflow solution providers, such as Thermo Fisher Scientific, in streamlining pre-manufacturing workflows, identifying bottlenecks, and proposing solutions.
The significant cost savings for the CDMO and refocusing of the organization towards their core mission that can be achieved through such solutions.
The benefits of a complete chemical workflow solution provider, including full supply chain support and delivery of customer-specified materials.
Fill out the form below to read the full article.
You May Also Like
